Preferred Label : Dresbuxelimab;
NCIt synonyms : Anti-CD73 Monoclonal Antibody AK119;
NCIt definition : A humanized monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster
of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating,
anti-viral and antineoplastic activities. Upon administration,dresbuxelimab targets
and binds to CD73 on tumor cells, thereby inhibiting the activity of CD73. This prevents
CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine
and the adenosine-mediated suppression of lymphocyte activity and trafficking. This
increases the activity of cytotoxic T-lymphocytes (CTLs), activates macrophages and
reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory
T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and
enhancing the CTL-mediated immune response against cancer cells, tumor cell growth
is decreased. In addition, dresbuxelimab may stimulate the production of anti-SARS-CoV-2
antibodies from B-cells which may lead to the rapid clearance of the virus. Also,
by inhibiting CD73, extracellular ATP levels are increased, which induces the production
of interferon-beta, and may enhance the cellular resistance to viral infection and
may trigger apoptosis of virus-infected cells. CD73, a plasma membrane protein belonging
to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types
and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable
nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression
within the tumor microenvironment (TME).;
UNII : QR3A4G4VHU;
CAS number : 2550560-20-6;
Molecule name : AK 119; AK-119;
NCI Metathesaurus CUI : CL1662167;
Origin ID : C179625;
UMLS CUI : C5667217;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
